Notes
The study was funded by Allergan, PLC.
Reference
Yehoshua A, et al. Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions. American Journal of Pharmacy Benefits : 2 Feb 2018. Available from: URL: https://www.ajpb.com/journals/ajpb/2018/AJPB_JanuaryFebruary2018/comparing-direct-medical-costs-of-onabotulinumtoxina-with-other-common-overactive-bladder-interventions
Rights and permissions
About this article
Cite this article
OnabotulinumtoxinA least costly option in OAB. PharmacoEcon Outcomes News 796, 21 (2018). https://doi.org/10.1007/s40274-018-4695-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4695-7